MX369874B - Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel. - Google Patents
Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel.Info
- Publication number
- MX369874B MX369874B MX2013014040A MX2013014040A MX369874B MX 369874 B MX369874 B MX 369874B MX 2013014040 A MX2013014040 A MX 2013014040A MX 2013014040 A MX2013014040 A MX 2013014040A MX 369874 B MX369874 B MX 369874B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- gel
- inhibiting
- drug
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica, inhibidora de la enzima fosfodiesterasa que contiene 1 - ((3 - (6,7 - dihidro - 1 - metil - 7 - oxo - 3 - propil - 1 H-pirazolo (4,3 - d) pirimidin - 5 - il) - 4 - etoxifenil) sulfonil) - 4- met ilpiperazina, como agente activo asociado con uno o mas excipientes farmacéuticamente aceptables; en la forma farmacéutica en sobres de gel o en un dispositivito dosificador.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2013014040A MX369874B (es) | 2013-11-29 | 2013-11-29 | Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel. |
PCT/IB2014/066410 WO2015101849A1 (es) | 2013-11-29 | 2014-11-28 | Composición farmacéutica para el tratamiento de la disfunción eréctil a base de un fármaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2013014040A MX369874B (es) | 2013-11-29 | 2013-11-29 | Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel. |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014040A MX2013014040A (es) | 2015-05-28 |
MX369874B true MX369874B (es) | 2019-11-22 |
Family
ID=53493336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014040A MX369874B (es) | 2013-11-29 | 2013-11-29 | Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel. |
Country Status (2)
Country | Link |
---|---|
MX (1) | MX369874B (es) |
WO (1) | WO2015101849A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2120570T3 (pl) * | 2007-02-12 | 2012-10-31 | Vyrix Pharmaceuticals Inc | Leczenie współwystępującego przedwczesnego wytrysku i zaburzenia wzwodu prącia |
US20090047330A1 (en) * | 2007-08-17 | 2009-02-19 | Ramesh Bangalore | Oral fast dissolving films for erectile dysfunction bioactive agents |
DE102009033396A1 (de) * | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
DK2415532T3 (en) * | 2010-08-02 | 2015-11-16 | Nch Corp | Component washing apparatus and method for washing components |
-
2013
- 2013-11-29 MX MX2013014040A patent/MX369874B/es active IP Right Grant
-
2014
- 2014-11-28 WO PCT/IB2014/066410 patent/WO2015101849A1/es active Application Filing
Also Published As
Publication number | Publication date |
---|---|
MX2013014040A (es) | 2015-05-28 |
WO2015101849A1 (es) | 2015-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201803699YA (en) | 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist | |
PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
UA111804C2 (uk) | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK) | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
BR112015010663A8 (pt) | formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo | |
BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
WO2015070224A3 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
MX2016001788A (es) | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx. | |
PH12014501991B1 (en) | Phenicol antibacterials | |
EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
PH12015502118A1 (en) | Pyridin-4-yl derivatives | |
PH12017501280B1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
PH12015502632A1 (en) | Cxcr7 receptor modulators | |
MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
MX2019010330A (es) | Formulaciones con mejora de la estabilidad. | |
EA201991287A1 (ru) | Твердые фармацевтические композиции на основе тикагрелора для перорального применения | |
NZ630033A (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride | |
MX369874B (es) | Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel. | |
PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis | |
MX2015014657A (es) | Nuevos agentes antibacterianos de fenicol. | |
EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
UA88315U (en) | Antibacterial composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |